ATE130517T1 - Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff. - Google Patents

Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.

Info

Publication number
ATE130517T1
ATE130517T1 AT91113173T AT91113173T ATE130517T1 AT E130517 T1 ATE130517 T1 AT E130517T1 AT 91113173 T AT91113173 T AT 91113173T AT 91113173 T AT91113173 T AT 91113173T AT E130517 T1 ATE130517 T1 AT E130517T1
Authority
AT
Austria
Prior art keywords
agent containing
inhibiting angiogenesis
intravascular embolizing
agent
substance inhibiting
Prior art date
Application number
AT91113173T
Other languages
English (en)
Inventor
Hiroaki Okada
Shigeru Kamei
Toshio Yoshioka
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE130517T1 publication Critical patent/ATE130517T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
AT91113173T 1990-08-08 1991-08-06 Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff. ATE130517T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21062290 1990-08-08
JP632391 1991-01-23

Publications (1)

Publication Number Publication Date
ATE130517T1 true ATE130517T1 (de) 1995-12-15

Family

ID=26340431

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91113173T ATE130517T1 (de) 1990-08-08 1991-08-06 Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.

Country Status (6)

Country Link
US (1) US5202352A (de)
EP (1) EP0470569B1 (de)
JP (1) JP2001039869A (de)
AT (1) ATE130517T1 (de)
CA (1) CA2048544C (de)
DE (1) DE69114782T2 (de)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0602586B1 (de) * 1992-12-16 1997-06-04 Takeda Chemical Industries, Ltd. Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
AU771815B2 (en) * 1993-07-19 2004-04-01 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
CA2472404A1 (en) * 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
AU728873B2 (en) * 1993-07-19 2001-01-18 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
ATE177632T1 (de) * 1993-09-24 1999-04-15 Takeda Chemical Industries Ltd Antineoplastische pharmazeutische zusammensetzung enthaltend ein fumagillolderivat und einen platinkomplex
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
JP2535785B2 (ja) * 1994-06-03 1996-09-18 工業技術院長 血管塞栓剤
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
ES2232711T3 (es) * 1995-07-27 2005-06-01 Micro Therapeutics, Inc. Composiciones de embolizacion.
US5667767A (en) * 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5580568A (en) * 1995-07-27 1996-12-03 Micro Therapeutics, Inc. Cellulose diacetate compositions for use in embolizing blood vessels
KR970069028A (ko) * 1996-04-01 1997-11-07 김은영 화학색전용 에멀젼의 제조방법
EP0928195B1 (de) * 1996-05-31 2003-01-02 Micro Therapeutics, Inc. Zusammensetzungen zur verwendung bei der embolisierung von blutgefässen
SK163598A3 (en) 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
US5695480A (en) * 1996-07-29 1997-12-09 Micro Therapeutics, Inc. Embolizing compositions
US5925683A (en) * 1996-10-17 1999-07-20 Target Therapeutics, Inc. Liquid embolic agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
JP2001524096A (ja) * 1997-04-24 2001-11-27 ニコムド イメージング エイエス コントラスト剤を含む不溶性微粒子または小胞を使用する塞栓治療
GB9727518D0 (en) * 1997-12-31 1998-02-25 Nycomed Imaging As Use
EP0927558A1 (de) * 1997-12-31 1999-07-07 Nycomed Imaging As Tenside enthaltendes Mittel zum Embolisieren
US6660301B1 (en) * 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
WO1999055396A1 (en) 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
FR2784580B1 (fr) * 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US6531111B1 (en) * 1999-05-21 2003-03-11 Micro Therapeutics, Inc. High viscosity embolizing compositions
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
WO2001003666A2 (en) * 1999-07-12 2001-01-18 Scimed Life Systems, Inc. Liquid based vaso-occlusive compositions
KR100591767B1 (ko) * 1999-09-09 2006-06-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 탁산의 맥관형성 혈관 전달을 위한 양이온성 리포좀
EP1250155B1 (de) 1999-12-22 2008-04-16 The Scripps Research Institute Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit
EP1263803B1 (de) 2000-03-13 2007-09-19 BioCure, Inc. Embolische zusammensetzungen
JP5460939B2 (ja) * 2000-03-13 2014-04-02 バイオコンパティブルズ ユーケー リミテッド ヒドロゲル生物医学用製品
US7338657B2 (en) * 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
EP1274472A2 (de) 2000-03-20 2003-01-15 Biosphere Medical, Inc. Injizierbare und schwellfähige mikrokügelchen zur gewebeverstärkung
US6436424B1 (en) 2000-03-20 2002-08-20 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
DE01918975T1 (de) * 2000-03-24 2006-04-13 Biosphere Medical, Inc., Rockland Mikrokügelchen zur aktiven Embolisierung
US6355275B1 (en) 2000-06-23 2002-03-12 Carbon Medical Technologies, Inc. Embolization using carbon coated microparticles
US6394965B1 (en) 2000-08-15 2002-05-28 Carbon Medical Technologies, Inc. Tissue marking using biocompatible microparticles
JP4817088B2 (ja) * 2000-10-10 2011-11-16 株式会社林原生物化学研究所 塞栓材料
DE60133053T2 (de) 2000-10-16 2009-02-26 Conor Medsystems, Inc., Menlo Park Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
CA2424345A1 (en) * 2000-10-16 2002-04-25 Neopharm, Inc. Liposomal formulation of mitoxantrone
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US6648911B1 (en) 2000-11-20 2003-11-18 Avantec Vascular Corporation Method and device for the treatment of vulnerable tissue site
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US6964680B2 (en) 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
EP1393069A1 (de) * 2001-05-24 2004-03-03 The University Of Florida Verfahren und vorrichtung zur rauchaussetzungfeststellung
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7131997B2 (en) * 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7053134B2 (en) * 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7341716B2 (en) * 2002-04-12 2008-03-11 Boston Scientific Scimed, Inc. Occlusive composition
US7670623B2 (en) 2002-05-31 2010-03-02 Materials Modification, Inc. Hemostatic composition
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
WO2003105917A2 (en) * 2002-06-12 2003-12-24 Scimed Life Systems, Inc. Bulking agents
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
JP4393098B2 (ja) * 2002-06-21 2010-01-06 独立行政法人科学技術振興機構 アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
EP1380263B1 (de) * 2002-07-12 2007-08-29 MYCRONA Gesellschaft für innovative Messtechnik mbH Verfahren und Vorrichtung zur Bestimmung der Ist-Position einer Struktur eines Untersuchungsobjektes
US7842377B2 (en) 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en) * 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
WO2004035022A2 (en) * 2002-10-15 2004-04-29 Microtherapeutics, Inc. Prepolymeric materials for site specific delivery to the body
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7588825B2 (en) * 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7560160B2 (en) * 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040161466A1 (en) 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
US7662783B2 (en) * 2003-02-20 2010-02-16 New York University CLK-peptide and SLK-peptide
US7601694B2 (en) * 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
US7007972B1 (en) 2003-03-10 2006-03-07 Materials Modification, Inc. Method and airbag inflation apparatus employing magnetic fluid
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
US6982501B1 (en) 2003-05-19 2006-01-03 Materials Modification, Inc. Magnetic fluid power generator device and method for generating power
US7169179B2 (en) 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7200956B1 (en) 2003-07-23 2007-04-10 Materials Modification, Inc. Magnetic fluid cushioning device for a footwear or shoe
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
US20050090804A1 (en) * 2003-10-22 2005-04-28 Trivascular, Inc. Endoluminal prosthesis endoleak management
US7901770B2 (en) * 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
WO2005079508A2 (en) * 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
CN101072797B (zh) 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
JP2007532187A (ja) 2004-04-06 2007-11-15 サーモディクス,インコーポレイティド 生物活性物質のためのコーティング組成物
US20050238870A1 (en) * 2004-04-22 2005-10-27 Marcia Buiser Embolization
US7311861B2 (en) * 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
KR101172722B1 (ko) * 2004-06-15 2012-08-16 폴리메딕스, 인코포레이티드 다가양이온성 화합물 및 이의 용도
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US8425550B2 (en) 2004-12-01 2013-04-23 Boston Scientific Scimed, Inc. Embolic coils
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) * 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US20060216237A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Inhibition of angiogenesis and tumor development by IGFBP-4
US20060216236A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Methods of inhibiting alphavBeta3-mediated angiogenesis and tumor development
US20060240002A1 (en) * 2005-03-11 2006-10-26 Brooks Peter C Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
KR20140090270A (ko) 2005-05-09 2014-07-16 바이오스피어 메디칼 에스.에이. 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및 방법
US20070004973A1 (en) * 2005-06-15 2007-01-04 Tan Sharon M L Tissue treatment methods
US9463426B2 (en) * 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
EP1934867A2 (de) * 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20070083219A1 (en) * 2005-10-12 2007-04-12 Buiser Marcia S Embolic coil introducer sheath locking mechanisms
US8007509B2 (en) 2005-10-12 2011-08-30 Boston Scientific Scimed, Inc. Coil assemblies, components and methods
US20070142859A1 (en) * 2005-12-19 2007-06-21 Boston Scientific Scimed, Inc. Embolic coils
US8101197B2 (en) 2005-12-19 2012-01-24 Stryker Corporation Forming coils
US8152839B2 (en) 2005-12-19 2012-04-10 Boston Scientific Scimed, Inc. Embolic coils
US7947368B2 (en) * 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US20070142560A1 (en) * 2005-12-21 2007-06-21 Young-Ho Song Block copolymer particles
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
WO2007090127A2 (en) * 2006-01-30 2007-08-09 Surgica Corporation Compressible intravascular embolization particles and related methods and delivery systems
WO2007090130A2 (en) * 2006-01-30 2007-08-09 Surgica Corporation Porous intravascular embolization particles and related methods
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
US20070299461A1 (en) * 2006-06-21 2007-12-27 Boston Scientific Scimed, Inc. Embolic coils and related components, systems, and methods
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US8414927B2 (en) 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
JP2010512230A (ja) * 2006-12-11 2010-04-22 プルーロームド インコーポレイテッド 灌流臓器止血法
US20080145658A1 (en) * 2006-12-15 2008-06-19 Boston Scientific Scimed, Inc. Freeze Thaw Methods For Making Polymer Particles
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090068684A1 (en) * 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US9642693B2 (en) * 2007-04-13 2017-05-09 W. L. Gore & Associates, Inc. Medical apparatus and method of making the same
US20080255678A1 (en) * 2007-04-13 2008-10-16 Cully Edward H Medical apparatus and method of making the same
US9717584B2 (en) * 2007-04-13 2017-08-01 W. L. Gore & Associates, Inc. Medical apparatus and method of making the same
EP2145902A3 (de) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8226701B2 (en) 2007-09-26 2012-07-24 Trivascular, Inc. Stent and delivery system for deployment thereof
US8663309B2 (en) 2007-09-26 2014-03-04 Trivascular, Inc. Asymmetric stent apparatus and method
US8066755B2 (en) 2007-09-26 2011-11-29 Trivascular, Inc. System and method of pivoted stent deployment
AU2008308474B2 (en) 2007-10-04 2014-07-24 Trivascular, Inc. Modular vascular graft for low profile percutaneous delivery
WO2009064697A2 (en) * 2007-11-13 2009-05-22 Boston Scientific Scimed, Inc. Combination coil and liquid embolic for embolization
US8083789B2 (en) 2007-11-16 2011-12-27 Trivascular, Inc. Securement assembly and method for expandable endovascular device
US8328861B2 (en) 2007-11-16 2012-12-11 Trivascular, Inc. Delivery system and method for bifurcated graft
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
CN104043125B (zh) 2008-04-10 2018-01-12 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
US8246876B2 (en) * 2008-08-18 2012-08-21 Cook Medical Technologies Llc Embolization particles and method for making same
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
CN102143996A (zh) * 2008-10-30 2011-08-03 大卫·刘 微球形多孔可生物相容支架及制造该支架的方法和装置
CN101536986B (zh) * 2009-04-16 2011-05-04 北京圣医耀科技发展有限责任公司 含索拉非尼的海藻酸钠靶向缓释微球血管栓塞剂及其制备和应用
DE102009051575A1 (de) * 2009-10-26 2011-04-28 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Verwendung von biokompatiblen Zusammensetzungen und hieraus polymerisierten Materialien zur Inhibierung der Angiogenese
CN103442742B (zh) 2011-03-30 2016-08-10 东丽株式会社 生物降解性粒子、血管栓塞材料及生物降解性粒子的制造方法
CN104203299B (zh) 2012-03-28 2016-08-17 东丽株式会社 生物降解性材料以及生物降解性材料的制造方法
ES2613484T3 (es) 2012-03-28 2017-05-24 Toray Industries, Inc. Material biodegradable y procedimiento de producción de material biodegradable
CA2868883C (en) 2012-03-30 2022-10-04 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US8992595B2 (en) 2012-04-04 2015-03-31 Trivascular, Inc. Durable stent graft with tapered struts and stable delivery methods and devices
US9498363B2 (en) 2012-04-06 2016-11-22 Trivascular, Inc. Delivery catheter for endovascular device
US10695440B2 (en) 2012-05-24 2020-06-30 Biosphere Medical, Inc. Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion
US20150080940A1 (en) * 2013-09-13 2015-03-19 Cook Medical Technologies Llc Anti-tumor macrophage m1 morphology inducer
KR102323637B1 (ko) 2013-09-16 2021-11-08 바이오컴페터블즈 유케이 리미티드 유성 조성물
RU2613888C1 (ru) * 2016-02-26 2017-03-21 государственное бюджетное учреждение здравоохранения "Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)" Способ предоперационного лечения больных с местно-распространенным раком шейки матки T1b2-T2b стадии
RU2619341C1 (ru) * 2016-08-29 2017-05-15 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ коррекции гормонального статуса при посткастрационном синдроме у больных раком шейки матки репродуктивного возраста
EP4026849A1 (de) 2016-09-26 2022-07-13 Ensemble Group Holdings Verfahren zur beurteilung und behandlung von krebs bei menschen mit dysregulierten lymphatischen systemen unter verwendung einer kombination aus vegfr-3 und pd-1- oder pd-l1-inhibitoren
JP6383133B1 (ja) * 2018-02-21 2018-08-29 国立大学法人信州大学 液体塞栓剤組成物
EP3888708B1 (de) * 2018-11-30 2024-01-03 Nextbiomedical Co., Ltd. Hydrogelpartikel zur chemoembolisation mit biologisch abbaubarem polymer
WO2026009810A1 (ja) * 2024-07-03 2026-01-08 住友ベークライト株式会社 血管塞栓剤、血管塞栓用キット、及び血管塞栓剤の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420565B (sv) * 1974-06-06 1981-10-19 Pharmacia Ab Hjelpmedel for intravaskuler administraring for anvendning i samband med intravaskuler administrering av en losning eller en suspension av ett diagnostiseringsmedel
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
ES2059571T3 (es) * 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd Fumagilina como agente angiostatico.
CA1329771C (en) * 1988-09-01 1994-05-24 Shoji Kishimoto Angiogenesis inhibitory agent
EP0682020A1 (de) * 1988-09-01 1995-11-15 Takeda Chemical Industries, Ltd. Fumagillolderivate verwendbar als Angiogeneseinhibitoren
EP0386667B1 (de) * 1989-03-06 1993-11-18 Takeda Chemical Industries, Ltd. 6-Amino-6-desoxyfumagillole, ihre Herstellung und ihre Verwendung
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof

Also Published As

Publication number Publication date
CA2048544C (en) 2002-01-01
EP0470569B1 (de) 1995-11-22
CA2048544A1 (en) 1992-02-09
EP0470569A1 (de) 1992-02-12
DE69114782D1 (de) 1996-01-04
JP2001039869A (ja) 2001-02-13
US5202352A (en) 1993-04-13
DE69114782T2 (de) 1996-04-18

Similar Documents

Publication Publication Date Title
ATE130517T1 (de) Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
AP9600794A0 (en) Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflammatory diseases
HU9302366D0 (en) Conjugates of interferons and method for producing them
ATE184789T1 (de) Verwendung von carnosolsäure wegen seiner anticarcinogenen und antiviralen eigenschaften
DE69228347D1 (de) Parfümteilchen enthaltende Textilbehandlungsmittel
EP0446636A3 (en) External application base or auxiliary agent and external application composition for human being or animal containing the same
BR9205313A (pt) Composiçáo bioativa
JPS5271471A (en) 1*2*44triazole compound and pasteurizing agent containing the same
IL98070A0 (en) Muteins of the granulocyte colony stimulating factor(g-csf)and pharmaceutical compositions containing them
GB2228200B (en) Insecticide treatment and compositions therefor
FI910088A0 (fi) Oral farmaceutisk komposition.
DE69131284D1 (de) Sekretionskörper enthaltende Zusammensetzung
NZ225393A (en) Cyclodextrin/bis-biguanido hexane complexes and pharmaceutical compositions containing them
IL101020A0 (en) Gallium complexes and pharmaceutical compositions containing them
IL67940A0 (en) 2,3-diaryl-5-halo-thiophenes,their preparation and pharmaceutical compositions containing them
ATE45286T1 (de) Gammainterferon und lymphotoxin enthaltende synergistische zusammensetzung und ihre herstellung.
FI943880A0 (fi) Muunnetu kasvaimen sytotoksinen tekijä
GB9007730D0 (en) Therapeutic compound and composition
ITMI912738A0 (it) Complessi del ferro con la conalbumina e i suoi derivati
BR9304405A (pt) Composição contendo carbonila
FI930269A7 (fi) Koostumus, joka aikaansaa bioaktiivisten aineiden parannetun poistuman verivirrasta
BR9100866A (pt) Resina e composicao de resina de copoliester
DE3176311D1 (en) Substituted 2-hydroxyphenyl cycloalkanes and pharmaceutical compositions thereof
IE900460L (en) Pharmaceutical composition
EP0092386A3 (en) Hydantoin therapeutic agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties